Dr Peters current work is focused on use of different antihypertensives, frailty and risk and benefit of treatment in the very elderly.
Between 2010 and 2012 Dr Peters was part of the core team setting up and developing the Imperial Clinical Trials Unit (ICTU). ICTU was launched in 2010 and is a fully UKCRC registered trials unit.
Prior to 2010 she led the multinational HYpertension in the Very Elderly Trial Cognitve function (HYVET-COG) study and co-ordinated the main Hypertension in the Very Elderly [HYVET] trial. HYVET was an Imperial sponsored multinational double blind RCT which was rated ‘Trial of the year’ by the Society for Clinical Trials and an exceptional landmark in medicine(F1000) in 2008. The HYVET trial results have changed global guidelines for the use of antihypertensive treatment in older adults (>=80 years).
Research interests include risk factors for dementia, particularly cardiovascular risk factors and potential interventions to ameliorate or prevent cognitive decline and dementia.
Anstey KJ, Peters R, 2018, Alcohol and dementia - risk or protective factor?, Nature Reviews Neurology, Vol:14, ISSN:1759-4758, Pages:635-636
VARIABLE BRAIN consortium, 2018, The association between blood pressure variability (BPV) with dementia and cognitive function: a systematic review and meta-analysis protocol., Syst Rev, Vol:7
et al., 2018, Exploiting Drug-Apolipoprotein E Gene Interactions in Hypertension to Preserve Cognitive Function: The 3-City Cohort Study., J Am Med Dir Assoc
et al., 2018, Orthostatic hypotension and symptomatic subclinical orthostatic hypotension increase risk of cognitive impairment: an integrated evidence review and analysis of a large older adult hypertensive cohort, European Heart Journal, Vol:39, ISSN:0195-668X, Pages:3135-3143
et al., 2018, Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study, International Psychogeriatrics, Vol:30, ISSN:1041-6102, Pages:1345-1354